Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer

KRAS mutations are associated with tumor resistance to EGFR TKIs (erlotinib, gefitinib) and to monoclonal antibody against EGFR (cetuximab). Targeted treatment of mutated RAS patients is still considered as a challenge. Inhibitors of c-Met (onartuzumab or tiwantinib) and MEK (selumetinib—a dual inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicoś, Marcin, Krawczyk, Paweł, Jarosz, Bożena, Sawicki, Marek, Szumiłło, Justyna, Trojanowski, Tomasz, Milanowski, Janusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4844634/
https://www.ncbi.nlm.nih.gov/pubmed/25902737
http://dx.doi.org/10.1007/s10238-015-0349-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4844634/
https://www.ncbi.nlm.nih.gov/pubmed/25902737
http://dx.doi.org/10.1007/s10238-015-0349-2

Ejemplares similares